These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 1657201)
1. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer. Gadducci A; Ferdeghini M; Prontera C; Moretti L; Pellagatta L; Bianchi R; Fioretti P J Nucl Biol Med (1991); 1991; 35(1):33-7. PubMed ID: 1657201 [TBL] [Abstract][Full Text] [Related]
2. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929 [TBL] [Abstract][Full Text] [Related]
3. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data. Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365 [TBL] [Abstract][Full Text] [Related]
4. [Significance of CA 125 antigen levels in patients with ovarian cancer]. Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806 [TBL] [Abstract][Full Text] [Related]
5. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer. Koelbl H; Schieder K; Neunteufel W; Bieglmayer C Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933 [TBL] [Abstract][Full Text] [Related]
6. Role of Ca 125 as tumor marker in ovarian carcinoma. Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052 [TBL] [Abstract][Full Text] [Related]
7. [Application of monoclonal antibody OC 125 in gynecological oncology]. Wu AR; Wang EY; Wang XX; Jia XH; Li L Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653 [TBL] [Abstract][Full Text] [Related]
8. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases]. Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340 [TBL] [Abstract][Full Text] [Related]
9. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer]. Schelling M; Jänicke F; Senekowitsch R; Lörken A Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138 [No Abstract] [Full Text] [Related]
10. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Ayhan A; Guven S; Guven ES; Kucukali T Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer. Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265 [TBL] [Abstract][Full Text] [Related]
13. Significance of some tumor markers in differential diagnosis of ovarian tumor. Zakrzewska I; Borawska R; Poznański J; Maćkowiak B Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438 [TBL] [Abstract][Full Text] [Related]
14. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms. Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567 [TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Peters-Engl C; Medl M; Ogris E; Leodolter S Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854 [TBL] [Abstract][Full Text] [Related]
16. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353 [TBL] [Abstract][Full Text] [Related]
17. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395 [TBL] [Abstract][Full Text] [Related]
18. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164 [TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125. Suzuki M; Sekiguchi I; Tamada T Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620 [TBL] [Abstract][Full Text] [Related]
20. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]